Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8472280 | 0.82 | SLC6A2 (0.60) | SLC6A4SLC6A3SLC6A2CYP2D6ADRB1 | |
| SCHEMBL23632333 | 0.77 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2CYP2D6ADRB1 | |
| SCHEMBL23632331 | 0.77 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2CYP2D6ADRB1 | |
| SCHEMBL28596325 | 0.76 | USP2 (0.49) | SLC6A4SLC6A3SLC6A2ADRB1USP2 | |
| SCHEMBL1473008 | 0.76 | USP2 (0.49) | SLC6A4SLC6A3SLC6A2ADRB1USP2 | |
| SCHEMBL29688057 | 0.76 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2CYP2D6ADRB1 | |
| SCHEMBL30857705 | 0.74 | ADRB1 (0.42) | SLC6A4SLC6A3SLC6A2CYP2D6ADRB1 | |
| SCHEMBL19948059 | 0.72 | CYP2D6 (0.39) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL19948060 | 0.72 | CYP2D6 (0.39) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL2258781 | 0.71 | SLC6A2 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | ALTMANN EVA | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | SLC6A4 2981/4885SLC6A3 4190/4885SLC6A2 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.